Active-site mTOR inhibitors augment HSV1-dICP0 infection in cancer cells via dysregulated eIF4E/4E-BP axis

Zakaria, Chadi; Sean, Polen; Hoang, Huy-Dung; Leroux, Louis-Phillipe; Watson, Margaret; Tekeste Workenhe, Samuel; Hearnden, Jaclyn; Pearl, Dana; Truong, Vinh Tai; Robichaud, Nathaniel; Yanagiya, Akiko; Tahmasebi, Soroush; Jafarnejad, Seyed Mehdi; Jia, Jian-Jun; Pelin, Adrian; Diallo, Jean-Simon; Le Boeuf, Fabrice; Bell, John Cameron; Mossman, Karen Louise; Graber, Tyson; Jaramillo, Maritza ORCID: https://orcid.org/0000-0002-1910-5684; Sonenberg, Nahum et Alain, Tommy (2018). Active-site mTOR inhibitors augment HSV1-dICP0 infection in cancer cells via dysregulated eIF4E/4E-BP axis PLoS Pathogens , vol. 14 , nº 8:e1007264. pp. 1-23. DOI: 10.1371/journal.ppat.1007264.

Prévisualisation

PDF - Version publiée Télécharger (33MB) | Prévisualisation

Résumé

Herpes Simplex Virus 1 (HSV1) is amongst the most clinically advanced oncolytic virus platforms. However, efficient and sustained viral replication within tumours is limiting. Rapamycin can stimulate HSV1 replication in cancer cells, but active-site dual mTORC1 and mTORC2 (mammalian target of rapamycin complex 1 and 2) inhibitors (asTORi) were shown to suppress the virus in normal cells. Surprisingly, using the infected cell protein 0 (ICP0)-deleted HSV1 (HSV1-dICP0), we found that asTORi markedly augment infection in cancer cells and a mouse mammary cancer xenograft. Mechanistically, asTORi repressed mRNA translation in normal cells, resulting in defective antiviral response but also inhibition of HSV1-dICP0 replication. asTORi also reduced antiviral response in cancer cells, however in contrast to normal cells, transformed cells and cells transduced to elevate the expression of eukaryotic initiation factor 4E (eIF4E) or to silence the repressors eIF4E binding proteins (4E-BPs), selectively maintained HSV1-dICP0 protein synthesis during asTORi treatment, ultimately supporting increased viral replication. Our data show that altered eIF4E/4E-BPs expression can act to promote HSV1-dICP0 infection under prolonged mTOR inhibition. Thus, pharmacoviral combination of asTORi and HSV1 can target cancer cells displaying dysregulated eIF4E/4E-BPs axis.

Type de document:	Article
Mots-clés libres:	-
Centre:	Centre INRS-Institut Armand Frappier
Date de dépôt:	08 août 2019 01:46
Dernière modification:	15 févr. 2022 18:14
URI:	https://espace.inrs.ca/id/eprint/8190

Gestion Actions (Identification requise)

Modifier la notice